Experts opinion on the laboratory diagnosis and treatment of invasive fungal infection secondary to severe novel coronavirus pneumonia

Abstract

Abstract:

The morbidity rate and transmissibility of the novel coronavirus of zoonotic origin (COVID-19) infected pneumonia are high, and the fatality rate among severe cases is high. Severe cases have risk factors of invasive fungal infections (IFIs), with some of them being reported to have developed combined or secondary fungal infections. To minimize the fatality rate among severe cases, IFIs-related microbiological, serologic and molecular biology examinations should be aggressively applied for the early discovery of invasive fungal infections and the early usage of target antifungal agents.

Key words: novel coronavirus pneumonia, invasive, fungal infection, laboratory diagnosis, treatment

CLC Number:

R519

YU Jin, LIU Wei, CHEN Wei, ZHANG Xiao-mei, WAN Zhe, WANG Ai-ping, LI Ruo-yu. Experts opinion on the laboratory diagnosis and treatment of invasive fungal infection secondary to severe novel coronavirus pneumonia[J]. Chinese Journal of Mycology, 2020, 15(1): 1-5.

References

[1] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J/OL]. N Engl J Med,2020.doi:10.1056/NEJMoa2001316.
[2] Wang C, Horby PW, Hayden FG et al. A novel coronavirus outbreakof global health concern[J/OL]. The Lancet,2020.doi:10.1016/S0140-6736(20)30185-9.
[3] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019-novel coronavirus (2019-nCoV) pneumonia in Wuhan, China[J/OL].The Lancet,2020.https://doi.org/10.1016/S0140-6736(20)30211-7.
[4] 王爱霞. SARS合并真菌感染的治疗[J]. 临床药物治疗杂志,2003,1(2):4-5.
[5] 雷红, 匡铁吉, 梁艳, 等. SARS患者合并细菌和真菌感染的分析[J]. 临床检验杂志,2004,22(3):171.
[6] Vanderbeke L, Spriet I, Breynaert C,et al. Invasive pulmonary aspergillosis complicating severe influenza:epidemiology, diagnosis and treatment[J]. Curr Opin infect Dis,2018, 31(6):471-480.
[7] 中华人民共和国国家卫生健康委员会办公厅,国家中医药管理局. 新型冠状病毒感染的肺炎诊疗方案(试行第五版)[S/OL].[2020-02-05]. http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
[8] 中国成人念珠菌病诊断与治疗专家共识组.中国成人念珠菌病诊断与治疗专家共识[J].中华内科杂志,2020,59(1):5-17.
[9] 中华医学会检验医学分会. 2019新型冠状病毒肺炎临床实验室生物安全防护专家共识[J]. 中华检验医学杂志, 2020,43(00):E001.
[10] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis,2019. https://doi.org/10.1093/cid/ciz1008.
[11] White PL, Barnes RA, Springer J, et al. Clinical performance of Aspergillus PCR for testing serum and plasma:a study by the European Aspergillus PCR Initiative[J]. J Clin Microbiol,2015, 53(9):2832-2837.
[12] Zhang S, Wang S, Wan Z,et al. Quantitative real-time PCR and Platelia galactomannan assay for the diagnosis of invasive pulmonary aspergillosis:bronchoalveolar lavage fluid performs better than serum in non-neutropaenic patients[J].Mycopathologia,2016,181(9-10):625-629.
[13] Chiu CY,Miller SA. Clinical metagenomics[J]. Nat Rev Genet,2019, 20(6):341-355.
[14] Patterson TF, Thompson GR 3rd, Denning DW,et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the infectious diseases society of America[J]. Clin Infect Dis,2016, 15;63(4):e1-e60.
[15] Cornely OA, Arikan-Akdagli S, Dannaoui E,et al. European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014, 20(Suppl 3):5-26.
[16] Perfect JR, Dismukes WE, Dromer F,et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of America[J].Clin Infect Dis, 2010, 50(3):291-322.